$27.64
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Wedbush Raises Price Target on Ultragenyx Pharmaceutical to $30 From $26, Keeps Neutral Rating
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating
Overview
52-week range
$18
$42
39% of range
Avg surprise (last 3)
-4.3%
Avg reaction (last 2)
-4.5%
50% positive
Latest IV / EM
112%
EM ±25.6% · $28 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-1.84 | $-1.55 | -18.7% | -17.2% | +0.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.81 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $-1.17 | $-1.27 | +7.9% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-1.57 | $-1.54 | -1.9% | — | -9.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.40 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.52 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-2.03 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.23 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.25 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 4, 2026 | Jun/2026 | OTHER | -$1.27 | -$1.17 | -8.6% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $136M | — | $160M | $166M | $139M | — | $139M | $147M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-169M | — | $-171M | $-108M | $-143M | — | $-132M | $-116M |
| Net income | $-185M | — | $-180M | $-115M | $-151M | — | $-134M | $-132M |
| EPS (diluted) | $-1.84 | — | $-1.81 | $-1.17 | $-1.57 | — | $-1.40 | $-1.52 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $175M | $421M | $203M | $176M | $127M | $174M | $151M | $481M |
| Inventory | $55M | $52M | $52M | $46M | $46M | $45M | $43M | $40M |
| Total current assets | $657M | $951M | $643M | $720M | $699M | $817M | $800M | $965M |
| Total assets | $1.30B | $1.53B | $1.19B | $1.31B | $1.31B | $1.50B | $1.54B | $1.62B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $1.52B | $1.60B | $1.17B | $1.15B | $1.16B | $1.24B | $1.18B | $1.19B |
| Total equity | $-236M | $-80M | $9M | $151M | $144M | $255M | $347M | $432M |